Search Results for: AC Immune SA to Receive
Articles
AC Immune SA to Receive Milestone Payment November 2, 2017
AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, recently...Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing With Personalized Cancer Vaccine April 17, 2024
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosing….
SAB Biotherapeutics Provides SAB-142 Trial Update April 16, 2024
SAB Biotherapeutics, Inc. recently announced its Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA, disclosed SAB has completed dosing the...NovelMed Receives FDA Orphan Drug Designation for Treating Paroxysmal Nocturnal Hemoglobinuria; Seeks Partnership April 15, 2024
NovelMed recently announced the US FDA has awarded Orphan Drug Designation (ODD) to NM5072, an Alternative Pathway (AP) blocker anti-Properdin antibody, for the treatment….
Exeliom Biosciences Announces Three Phase 2 Clinical Trials in Immuno-oncology With Lead Candidate Combined With Immune Checkpoint Inhibitors April 11, 2024
Exeliom Biosciences recently announced the launch of three Phase 2 clinical studies of its lead candidate EXL01 combined with immune...VACCINE DEVELOPMENT - Therapeutic Vaccines Development: At the Edge of a New Revolution March 28, 2024
Mario Davinelli, PhD, Narcisa Mesaros, MD, David Morland, and Judith Neville, PhD, say therapeutic vaccines are an exciting area of research that has the potential to revolutionize the way we treat diseases.
THERAPEUTIC FOCUS - Sarilumab Approval for Polymyalgia Rheumatica Highlights Enduring Unmet Medical Needs March 28, 2024
David A. Katz, PhD, and Robert Jacks, MBA, MSE, say a new, effective treatment option is now available, promotion of the drug will increase disease awareness, and the success encourages others in the industry to continue and expand their PMR research. However, the proportion of patients who can benefit from the drug is limited, and significant unmet needs remain for all persons suffering from PMR.
Vidac Pharma Receives Japanese Patent Office Notice of Allowance for Cancer Drug Candidate March 27, 2024
Vidac Pharma Holdings Plc. recently announced it has received a Notice of Allowance from the Japanese Patent Office for the...Intravacc Announces Positive Data of First in Human Intranasal OMV-Based Vaccine for SARS-CoV-2 March 26, 2024
Intravacc recently announced positive clinical data of a first in human (FIH) study of Avacc 10, an intranasal outer membrane...Sequel’s twiist Automated Insulin Delivery System Receives FDA 510(k) Clearance March 18, 2024
Device bundles latest technology to deliver significant advancements for insulin management for people with type 1 diabetes….
GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the UK March 4, 2024
GRI Bio, Inc. recently announced the authorization of its Clinical Trial Application (CTA) by the United Kingdom Medicines and Healthcare products...Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination With Bevacizumab in Advanced Ovarian Cancer February 27, 2024
IMUNON, Inc. recently announced Memorial Sloan Kettering Cancer Center has joined MD Anderson Cancer Center in enrolling patients in a...Biom Pharmaceutical Published Clinical Safety & Efficacy of Microbiome-Based Probiotic Suppositories for Intimate Women's Health February 27, 2024
Biom Pharmaceutical recently announced publication of the results of the clinical study on VagiBiom microbiome-based probiotic suppositories, the company’s flagship...Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer February 20, 2024
Immuneering Corporation recently announced the US FDA granted Fast Track designation for its lead clinical-stage program, IMM-1-104, for the treatment...BioNTech & DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate January 31, 2024
BioNTech SE and Duality Biologics recently announced the US FDA granted Fast Track designation for BNT325/DB-1305 for the treatment of patients with platinum-resistant ovarian epithelial cancer….
Longeveron Receives Notice of US Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B January 29, 2024
Longeveron Inc. recently announced it received a notice of patent allowance from the United States Patent and Trademark Office (PTO)...PolTREG Receives US Patent Office Notice of Allowance for Treg Cell Therapy to Treat Type-1 Diabetes January 16, 2024
PolTREG S.A. recently announced it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO), covering...Sitryx Announces Collaboration Partner Lilly Has Commenced Phase 1 Study of SIT-011 for Chronic Autoimmune & Inflammatory Diseases January 4, 2024
Sitryx Therapeutics recently announced Eli Lilly & Company has commenced a Phase 1 first-in-human study of SIT-011, a post-translational modification modulator program for chronic autoimmune and….
Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program January 3, 2024
Intensity Therapeutics, Inc. recently announced a business update reflecting progress in its Phase 3 sarcoma clinical program. In the fourth...GeoVax Announces Issuance of Malaria Vaccine Patent January 3, 2024
GeoVax Labs, Inc. recently announced the US Patent and Trademark Office has issued Patent No. 11,857,611 to GeoVax, pursuant to...
